Given that CML-iPSCs Ph+ lost their BCR-ABL1 dependency, we evaluated whether after hematopoietic re-differentiation, CD34+ hematopoietic progenitors derived from CML-iPSC Ph+ recovered their BCR-ABL1 addiction revealed by restored sensitivity to TKI. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.